Cargando…
CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
Identification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In thi...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951414/ https://www.ncbi.nlm.nih.gov/pubmed/24622579 http://dx.doi.org/10.1371/journal.pone.0091771 |